{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"28"}]}],"title":"Any non-SAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"12"}]}],"title":"Any SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence in a trial participant administered an investigational product(s), a comparator product, or an approved drug regardless of the causal relationship with treatment. An SAE is an AE that Results in death, life threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, results in a congenital anomaly/birth defect or any important medical events as per medical or scientific judgment. Adverse events which were not Serious were considered as Non-Serious adverse events.","groups":[{"description":"Participants who completed the randomized treatment period or discontinued treatment early for other reasons but completed scheduled assessments through Week 24 were enrolled in an open-label extended treatment period. Participants continued to receive 200 mg of MMB orally QD during the open-label extended treatment period.","id":"OG000","title":"MMB 200 mg QD- Open-Label Extended Treatment Period"},{"description":"Participants who completed the randomized treatment period, discontinued treatment early due to splenic progression, or discontinued treatment early for other reasons but completed scheduled assessments through Week 24 were enrolled in an open-label extended treatment period. Participants who received DAN 300 mg BID during randomized period switched to receive 200 mg of MMB orally QD during open-label extended treatment period.","id":"OG001","title":"DAN 300 mg BID to MMB 200 mg QD- Open-Label Extended Treatment Period"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set","reportingStatus":"POSTED","timeFrame":"From Week 24 to a maximum of 151 weeks","title":"Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs)- From Week 24 to a Maximum of 151 Weeks","type":"SECONDARY","unitOfMeasure":"Participants"}